Please wait while the formulary information is being retrieved.
ELITEK (RASBURICASE)
- Chemotherapy-induced hyperuricemia
1.5 mg intravenous solution
- Dosage information is not available
7.5 mg intravenous solution
- Infuse 0.15 mg/kg over 30 minute(s) by intravenous route once daily
1.5 mg intravenous solution
- Dosage information is not available
7.5 mg intravenous solution
- Infuse 0.15 mg/kg over 30 minute(s) by intravenous route once daily
Chemotherapy-induced hyperuricemia
- Infuse 0.15 mg/kg over 30 minute(s) by intravenous route once daily
- Infuse 0.15 mg/kg over 30 minute(s) by intravenous route once daily for 5 days
- Infuse 0.2 mg/kg over 30 minute(s) by intravenous route once daily
- Infuse 0.2 mg/kg over 30 minute(s) by intravenous route once daily for 5 days
- None
Contraindicated
- None
Severe
Moderate
- None
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Hemolysis
- Hemolytic anemia from PK and g6PD deficiencies
- Lactating mother
- Methemoglobinemia
Contraindicated
- None
Severe
Moderate
- None
ELITEK (RASBURICASE)
- Chemotherapy-induced hyperuricemia
- Hyperbilirubinemia
- Hypophosphatemia
- Severe dyspnea
- Stomatitis
- Acute abdominal pain
- Constipation
- Diarrhea
- Fever
- Headache disorder
- Nausea
- Peripheral edema
- Pharyngitis
- Skin rash
- Symptoms of anxiety
- Vomiting
More Frequent
Severe
Less Severe
- Bacterial sepsis
- Hyperphosphatemia
- Body fluid retention
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute renal failure
- Anaphylaxis
- Cardiac arrhythmia
- Chest pain
- Hemolysis
- Infection
- Methemoglobinemia
- Myocardial ischemia
- Seizure disorder
- Supraventricular arrhythmias
Less Severe
- Muscle spasm
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Rasburicase
- Severity Level:
C
- Additional Notes:
Contraindicated
Rasburicase
Insufficient data available;Should not be used if infant has g6Pd deficiency
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient data available;Should not be used if infant has g6Pd deficiency |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This drug can cause a severe allergic reaction. If you develop new symptoms such as chest pain, trouble breathing, severe dizziness, itching/swelling (especially of the face/tongue/throat), or rash/hives, stop using this medication and get medical help right away. Do not restart this medication if this severe allergic reaction has occurred.<br /><br />Consult the doctor or pharmacist for more details. Do not take this medication if you have a metabolic condition called glucose-6-phosphate dehydrogenase (G6PD) deficiency because it can severely damage your red blood cells leading to anemia (hemolysis). If you are of African or Mediterranean descent, you may be at higher risk for G6PD deficiency and you should be tested to see if you have this condition before starting this medication.<br /><br /> This medication can cause a condition that affects the ability of your red blood cells to carry oxygen (methemoglobinemia). Do not restart this medication if this effect occurs; consult the doctor for details. This medication can interfere with accurate measurement of uric acid in the blood, resulting in falsely low levels (see Drug Interactions section). Be sure to tell all laboratory personnel that you are using this drug.
| Chemotherapy-induced hyperuricemia | |
| E88.3 | Tumor lysis syndrome |
| 0-9 | A-Z |
|---|---|
| E88.3 | Tumor lysis syndrome |
Formulary Reference Tool